Ian Hamilton-Craig

Summary

Publications

  1. doi request reprint Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations
    Ian Hamilton-Craig
    Department of Cardiology, Gold Coast Hospital, Griffith University School of Medicine, and Griffith Health Institute, Heart Foundation Research Centre, Southport, Queensland, Australia
    Int J Evid Based Healthc 10:181-90. 2012
  2. pmc Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
    Ian Hamilton-Craig
    Griffith University School of Medicine, Southport, Queensland, Australia
    Vasc Health Risk Manag 6:1023-37. 2010
  3. doi request reprint At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy
    Ian Hamilton-Craig
    Department of Cardiology, Griffith University School of Medicine, Gold Coast Hospital, Southport, Queensland 4215, Australia
    Heart Lung Circ 18:343-6. 2009

Collaborators

Detail Information

Publications3

  1. doi request reprint Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations
    Ian Hamilton-Craig
    Department of Cardiology, Gold Coast Hospital, Griffith University School of Medicine, and Griffith Health Institute, Heart Foundation Research Centre, Southport, Queensland, Australia
    Int J Evid Based Healthc 10:181-90. 2012
    ..Fibrates are variably effective in lowering low-density cholesterol levels. Available fibrates include gemfibrozil, fenofibrate, bezafibrate, etiofibrate and ciprofobrate; only fenofibrate and gemfibrozil are available in Australia...
  2. pmc Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
    Ian Hamilton-Craig
    Griffith University School of Medicine, Southport, Queensland, Australia
    Vasc Health Risk Manag 6:1023-37. 2010
    ..One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH...
  3. doi request reprint At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy
    Ian Hamilton-Craig
    Department of Cardiology, Griffith University School of Medicine, Gold Coast Hospital, Southport, Queensland 4215, Australia
    Heart Lung Circ 18:343-6. 2009
    ..9% vs. 7.0%, p=0.03 and 4.1% vs. 2.5%, p=0.05, respectively). These differences were not related to any form of cancer and did not increase with increased duration of therapy...